What are the odds of developing cervical cancer?
Evidence quality 4.88/5
Eight-dimension review score against the quality rubric . Each dimension scored 1–5.
- D1 Source grounding
- 5/5
- D2 Source authority
- 5/5
- D3 Arithmetic
- 5/5
- D4 Uncertainty
- 5/5
- D5 Scope
- 5/5
- D6 Prose
- 5/5
- D7 Perception honesty
- 4/5
- D8 Caveat completeness
- 5/5
Lifetime probability · lifetime, subgroup
1 in 167
0.6% lifetime chance
Most people overestimate this.
range 1 in 250 to 1 in 111
● your factors — click this risk ▾ to reveal
≈ As likely as
Perceived
Cervical cancer sits in an unusual perceptual niche. Among women over 40, it is remembered as a major threat that screening and the Pap smear tamed — something their mothers worried about. Among women under 30, it is increasingly filed under "solved by the HPV vaccine." Both frames contain truth and both produce underestimates in specific directions: older women may not realise how much screening has reduced the absolute number, while younger women may not realise that the vaccine does not cover all oncogenic HPV strains and that over 20% of cervical cancers are diagnosed in women over 65 who may have aged out of screening. No high-quality US survey isolates "fear of cervical cancer" as a standalone probability question, so the perceived side is editorial intuition.
Rough estimate: Most US women sense it is 'rare now' but lack a concrete number; globally it remains a top-three cancer killer of women
Source: editorial intuition, not polled
Actual
~7.7 new cases per 100,000 women per year (US, 2018-2022 age-adjusted)
US women (all ages, age-adjusted, SEER 2018-2022)
Show derivation
SEER Cancer Stat Facts reports a lifetime risk of being diagnosed with cervical cancer of approximately 0.6% (about 1 in 167), based on 2018-2021 SEER data (excluding 2020 due to COVID screening disruption). The age-adjusted incidence rate is 7.7 per 100,000 women per year (2018-2022). Using the site-standard 59-year remaining-life horizon from age 18: 1 − (1 − 7.7e-5)^59 ≈ 0.00454, which is lower than the SEER actuarial estimate of 0.006 because SEER uses full life-table methods with age-specific incidence rates that peak in women aged 35-44 and remain elevated through old age. We use the SEER actuarial figure of 0.006 as the more accurate estimate. The death rate is 2.2 per 100,000 women per year (2019-2023), implying a lifetime mortality risk of roughly 0.2% (1 in 500). The uncertainty band (0.004-0.009) reflects the range between well-screened populations with HPV vaccination (where incidence is falling sharply) and under-screened populations (where incidence remains materially higher). The scope is subgroup_lifetime because the figure applies only to women / people with a cervix (roughly half of US adults), not to all US adults.
Caveats: The 0.6% lifetime incidence figure reflects the current US screening environment…
The 0.6% lifetime incidence figure reflects the current US screening environment, in which roughly 80% of eligible women receive cervical screening at recommended intervals. It is a population average across vaccinated and unvaccinated women. For cohorts fully vaccinated with the 9-valent HPV vaccine before sexual debut, the lifetime risk is likely to fall to 0.1% or lower, because the vaccine covers the HPV types responsible for roughly 90% of cervical cancers. Conversely, in countries with minimal screening infrastructure (much of Sub-Saharan Africa, parts of South and Southeast Asia), the incidence is 4-5x higher, and cervical cancer remains the second or third most common cancer in women. The 0.6% is an incidence figure, not a mortality figure; the lifetime mortality risk in the US is roughly 0.2% (1 in 500), reflecting a 5-year relative survival rate of ~67% across all stages. Racial disparities persist in the US: Black and Hispanic women have higher incidence and mortality than White women, driven largely by differences in screening access and HPV vaccination uptake. The incidence rate has been roughly stable for the past decade after declining by more than half from the mid-1970s; the next major decline is expected as fully vaccinated cohorts enter the peak-incidence age range.
Risks at similar odds
Other risks with roughly the same likelihood — useful for calibration.
Recently viewed on this device
Stored locally — clear anytime.
Pick challenger
SEER estimates that approximately 0.6% of US women — about 1 in 167 — will be diagnosed with cervical cancer over a lifetime, based on 2018-2021 data. The age-adjusted incidence rate is 7.7 per 100,000 women per year, and the death rate is 2.2 per 100,000, implying a lifetime mortality risk of roughly 1 in 500. That puts cervical cancer diagnosis at about half the lifetime odds of dying in a car crash and roughly one-twentieth the lifetime risk of breast cancer. The American Cancer Society projects 13,360 new cases and 4,320 deaths in 2025 — numbers that would have been roughly double in the 1970s before widespread Pap screening cut incidence by more than half.
The HPV vaccine is rewriting these numbers in real time. A 2024 JAMA study found that cervical cancer mortality among US women under 25 dropped 15.2% per year from 2013 to 2021, coinciding with the first cohorts vaccinated in adolescence reaching the age of diagnosis. The 9-valent vaccine covers the HPV types responsible for roughly 90% of cervical cancers, which means the 0.6% lifetime figure is a snapshot of a mixed population — partly vaccinated, partly not — and is headed downward. For a woman fully vaccinated before sexual debut, the lifetime risk is likely to settle near 0.1% or lower. Cervical cancer is one of the few malignancies for which near-elimination is plausible within a generation, conditional on vaccination uptake.
The caveat is that “near-elimination” is a wealthy-country projection. In Sub-Saharan Africa, where screening coverage is minimal and HPV prevalence is high, cervical cancer incidence runs 4-5x the US rate and remains the second or third most common cancer in women. HIV co-infection — which impairs HPV clearance and roughly sextuples cervical cancer risk — adds a compounding factor. Within the US, Black and Hispanic women carry higher incidence and mortality than White women, driven largely by disparities in screening access and vaccination uptake. Over 20% of US cervical cancers are diagnosed in women over 65, many of whom have aged out of routine screening — a reminder that the population-level success story does not distribute evenly.
Claim ledger
Every number below is what each source reported, with the verbatim quote we relied on and how we arrived at our figure. Click any link to verify directly.
-
[1] National Cancer Institute — Surveillance, Epidemiology, and End Results Program (SEER) — Cancer Stat Facts: Cervical Cancer
Cancer Stat Facts: Cervical Cancer- Statistic
Approximately 0.6% of women will be diagnosed with cervical cancer during their lifetime; incidence rate 7.7 per 100,000 women per year; death rate 2.2 per 100,000 per year- Excerpt
“"Approximately 0.6 percent of women will be diagnosed with cervical cancer at some point during their lifetime, based on 2018–2021 data. [...] The rate of new cases of cervical cancer was 7.7 per 100,000 women per year. [...] The death rate was 2.2 per 100,000 women per year based on 2019–2023." ”
- Source data from
- 2025-01-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- SEER provides the headline lifetime risk (0.6%) using actuarial life-table methods applied to age-specific incidence rates from 18 SEER registries covering approximately 48% of the US population. The 0.6% figure is used directly as the normalized estimate because SEER's actuarial method is more precise than a crude annual-rate compounding over 59 years. The incidence rate of 7.7 per 100,000 anchors the native display. The death rate of 2.2 per 100,000 implies that roughly 29% of diagnosed cases are fatal (2.2/7.7), reflecting the relatively favorable 5-year survival rate of ~67% for all stages combined.
-
[2] American Cancer Society — Key Statistics for Cervical Cancer
Key Statistics for Cervical Cancer- Statistic
Estimated 13,360 new cases and 4,320 deaths from cervical cancer in the US in 2025; incidence declined by more than half from the mid-1970s to mid-2000s due to screening- Excerpt
“"The American Cancer Society's estimates for cervical cancer in the United States for 2025 are: about 13,360 new cases of invasive cervical cancer will be diagnosed, and about 4,320 women will die from cervical cancer. [...] More than 20% of cervical cancers are found in women over 65." ”
- Source data from
- 2025-01-01
- Accessed
- 2026-04-18 · archived copy
- Calculation
- ACS provides the absolute case and death counts for 2025, which serve as a cross-check on the SEER rate-based figures. 13,360 new cases among ~170 million US women yields roughly 7.9 per 100,000, consistent with the SEER age-adjusted rate of 7.7. The >20% of cases in women over 65 anchors the caveat about screening cessation. ACS and SEER draw from overlapping but not identical data pipelines; ACS projections are modelled from SEER historical trends.
- Independence
- ACS projections are modelled from SEER data and NCHS mortality data, so they are not fully independent. The value is in the forward projection and the clinical context ACS adds around screening and HPV vaccination.
-
[3] JAMA — Cervical Cancer Mortality Among US Women Younger Than 25 Years, 1992-2021
Cervical Cancer Mortality Among US Women Younger Than 25 Years, 1992-2021- Statistic
Cervical cancer mortality among US women under 25 declined 15.2% per year from 2013-2015 to 2019-2021, following HPV vaccine introduction- Excerpt
“"From 2013-2015 to 2019-2021, mortality decreased 15.2% per year, coinciding with the time period when women who were age-eligible for HPV vaccination in 2006 would have entered the age range of 20-24 years." ”
- Source data from
- 2024-11-27
- Accessed
- 2026-04-18 · archived copy
- Calculation
- The JAMA study quantifies the HPV vaccine's impact on mortality in the first fully vaccinated cohort. A 15.2% annual decline is dramatic and suggests the 0.6% lifetime incidence figure will fall substantially for women born after ~1990 who were vaccinated. The current 0.6% reflects a mixed population of vaccinated and unvaccinated women; the uncertainty band's lower end (0.004) is where we expect the fully-vaccinated-cohort lifetime risk to settle, though this remains a projection. The study is methodologically independent of SEER incidence data (it uses NCHS mortality data directly).
- Independence
- Uses NCHS mortality data from CDC WONDER, not SEER incidence registries. Genuinely independent of the SEER source for the mortality trend.